Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | HTT | P42858 | 2/20 | 0.75 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.75 |
| ▸ | ESR1 | P03372 | 1/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101886 | 1.00 | ALDH1A1 (0.80) | ALDH1A1LMNAMAPTHTTESR2 | |
| SCHEMBL27475874 | 0.93 | LMNA (0.70) | ALDH1A1LMNAMAPTHTTESR2 | |
| SCHEMBL25398342 | 0.91 | RAB9A (0.70) | ALDH1A1LMNAMAPTHTTESR2 | |
| SCHEMBL52200 | 0.89 | ALDH1A1 (1.00) | ALDH1A1LMNAMAPTHTTESR2 | |
| SCHEMBL822185 | 0.89 | ALDH1A1 (1.00) | ALDH1A1LMNAMAPTHTTESR2 | |
| SCHEMBL14310920 | 0.88 | LMNA (0.61) | ALDH1A1LMNAMAPTHTTESR2 | |
| SCHEMBL18678546 | 0.88 | LMNA (0.61) | ALDH1A1LMNAMAPTHTTESR2 | |
| SCHEMBL10783506 | 0.88 | LMNA (0.61) | ALDH1A1LMNAMAPTHTTESR2 | |
| SCHEMBL12300250 | 0.88 | LMNA (0.61) | ALDH1A1LMNAMAPTHTTESR2 | |
| SCHEMBL12757099 | 0.88 | LMNA (0.61) | ALDH1A1LMNAMAPTHTTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0809490-A4 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0871436-A4 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0835104-A4 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0871436-A1 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0835104-A1 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0809490-A1 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997002023-A1 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-23 | — | — | WO | disclosed |
| WO-1997002024-A1 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-23 | — | — | WO | disclosed |
| CN-1135333-A | Usage of SRCSH2 specific compound for treatment of bone absorption disease | SMITHKLINE BEECHAM CORP (US) | 1996-11-13 | — | — | CN | disclosed |
| EP-0728482-A2 | Use of hcp specific compounds to enhance erythropoiesis | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0727211-A1 | Use of src SH2 specific compounds to treat a bone resorption disease | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-21 | — | — | EP | disclosed |
| WO-1996024343-A1 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-15 | — | — | WO | disclosed |